Kirkey DC, Robinson L, Janssens D, Hines MG, Hylkema T, Manselle MK, Ries RE, Peplinski JH, Wallace LK, Otto D, Tarlock K, Henikoff S, Li W, Meshinchi S (2023) CLEC2A is a novel AML-restricted immunotherapeutic target enriched in KMT2A-rearranged acute myeloid leukemia. Blood 142(1):290. doi: 10.1182/blood-2023-188439
Objective: Targeting CLEC2A, a novel immunotherapeutic target, in the treatment of acute myeloid leukemia.
Summary: CLEC2A, a novel immunotherapeutic target expressed highly in acute myeloid leukemia, is a potential target in treating leukemia. By conjugating an antibody targeting this protein to saporin, an ADC for the treatment of leukemia can be created.
Usage: A CLEC2A-antibody was conjugated to Hum-ZAP [IT-22] and treated against CLEC2A+ and CLEC2A- cells and target-specific cytotoxicity was observed at 10nM levels.
Related Products: Hum-ZAP (Cat. #IT-22)